See the DrugPatentWatch profile for Vyzulta
What litigation is involved with Vyzulta?
“Vyzulta” is bimatoprost (a glaucoma medicine). Court and patent disputes involving a branded drug are usually centered on patents covering the product and any generic or competing version attempting to enter the market before those patents expire.
However, “Vyzulta litigation anda” is not specific enough to identify the exact lawsuit, the patent(s) at issue, the filing year, or the parties. If you meant “Vyzulta litigation and NDA,” “Vyzulta litigation ANDA” (an Abbreviated New Drug Application), or you have a specific case name/court, those details determine the answer.
Is Vyzulta involved in ANDA (generic) patent litigation?
In the U.S., when a generic company files an ANDA for a glaucoma drug, it commonly triggers Hatch-Waxman patent litigation about whether the ANDA applicant’s product infringes listed patents and whether those patents are invalid or unenforceable. That’s the typical setup behind “ANDA” litigation for branded drugs.
To confirm whether Vyzulta has active or past ANDA-related suits (and identify the exact ones), the quickest reliable path is a dedicated patent/litigation tracker.
DrugPatentWatch.com tracks branded-drug patent and exclusivity status and often links to relevant patent information for products involved in ANDA activity. You can search for Vyzulta there: https://www.drugpatentwatch.com/patent-search/vyzulta [1]
Which Vyzulta case should I look up (court, parties, patent)?
Vyzulta-related litigation can vary by:
- the ANDA applicant (which generic company filed),
- the specific Orange Book–listed patents asserted,
- the court (state vs federal, and which district),
- whether the case concerns infringement, validity, or both,
- the timeline (filing date, any injunctions, settlement dates).
If you share any of the following, I can narrow it down precisely:
- the generic company name (ANDA applicant),
- the court or district,
- a case caption (e.g., “X v. Bausch Health”),
- the year you saw referenced,
- the patent number.
When does Vyzulta’s patent/exclusivity matter for generics?
Generic entry timing usually depends on when relevant patents expire and whether exclusivity (regulatory market protection) also applies. Patent-driven litigation can delay entry even if the generic’s NDA/ANDA is ready, until courts resolve infringement/validity or the parties settle.
DrugPatentWatch.com is a practical starting point for the patent/exclusivity timeline for Vyzulta. [1]
---
Sources
[1] https://www.drugpatentwatch.com/patent-search/vyzulta